Arcus’s near dream scenario
Gilead opts in at long last, and that’s more than many might have been expecting.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Calithera buys itself a plan B
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Supernus and Pacira swoop while their targets are down
Two opportunistic buys today, of Adamas and Flexion, included a contingent value rights component.
J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Merck & Co justifies paying up for Acceleron
But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.
Non-genetic amyloidosis lives again, thanks to Darzalex and Astra
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Valneva falls as UK contract axe falls
Valneva might have to look beyond the UK for vaccine sales after today's contract termination.
Sanofi makes another bolt-on with Kadmon
The “left field but logical” buy sees Sanofi gaining a graft-versus-host disease therapy to add to its transplant offering.
